Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Menopause
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Menopause
    Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data - (BMJ)
    TopAbstracts in Menopause 06/23/2009 - (DGNews)
    TopAbstracts in Menopause 06/09/2009 - (DGNews)
    FDA Approves Bi-Yearly Zoledronic Acid Injection to Prevent Osteoporosis in Postmenopausal Women - (DGNews)
    TopAbstracts in Menopause 05/26/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Menopause
    • Managing Insomnia in Older Women: A Case-Based Approach
    • Evaluation and Management of a 53-Year-Old Woman Presenting With Disturbed Sleep
    • Endocrinology and Management of Hormone Therapy in Older Women
      Vasomotor Symptoms: Managing the Transition from Perimenopause to Postmenopause
      Endocrinology and Management of Hormone Therapy in Older Women

      Webcasts/CME archive

       Recent cases - Menopause
        Female Sexual Dysfunction: Does Surgically Induced Menopause Matter?
        A Postmenopausal Woman Presenting with Atypical Symptoms and Cervical Cancer : A Case Report
        A Postmenopausal Woman Presenting with Ekbom Syndrome Associated with Recurrent Depressive Disorder: A Case Report
        Pyometra Presenting in Conjunction with Bowel Cancer in a Post-Menopausal Women: A Case Report
        Uterine Leiomyomas with Tubules

        Cases archive
          




        my personal edition > menopause > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Subcutaneous Oestradiol Implants Have Anabolic Effect On Bone

        A DGReview of :"The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women"
        British Journal of Obstetrics and Gynaecology

        08/07/2002
        By Anne MacLennan


        Oestrogen implants in postmenopausal women prompt an eventual large increase in bone mineral density.

        This is the suggestion of an evaluation of the anabolic effect of oestrogen on bone by researchers from the Division of Clinical Sciences (North), University of Sheffield, Sheffield, England.

        In a one-year, placebo controlled study, Dr C.A. Pereda and colleagues compared the response of markers of bone formation (and resorption) and bone mineral density (BMD) to subcutaneous oestradiol implants.

        The study, involving 21 postmenopausal women who had all undergone hysterectomy, found the oestrogen exerted an apparent anabolic effect, which was initially reflected by an increase in bone formation markers and later by a large increase in BMD.

        The women received either 25 mg oestradiol implants or a sham procedure at baseline and at six months.

        At baseline and one year, the researchers assessed the women's BMD and quantitative ultrasound (QUS). Also measured at baseline, and at four, eight, 12 and 24 weeks were bone alkaline phosphatase (bone ALP), procollagen type I N-terminal propeptide (PINP), osteocalcin (OC), free deoxypyridinoline (iFDPD), N-telopeptide of type I collagen (NTX), serum oestradiol and intact parathyroid hormone (PTH).

        Outcome measures were percentage change markers of bone turnover and PTH and change in oestradiol levels over the first six months and percentage of changes in DXA and QUS over one year.

        In women on oestrogen versus control subjects, PINP increased by 28 percent, bone ALP by 7 percent and OC by 9 percent in the first four weeks of treatment and then decreased significantly.

        During the first year of treatment, lumbar spine (LS) and total hip (TH) BMD increased by 5.4 percent and 6.0 percent respectively, and femoral neck (FN) BMD by 3.7 percent in women on oestrogen versus control subjects.

        Peak serum oestradiol level was achieved four weeks after implant insertion.

        Mean PTH levels increased significantly in women on subcutaneous oestradiol.
        BJOG: an International Journal of Obstetrics and Gynaecology, Vol. 109 (7) (2002) pp. 812-820. "The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send